Muscle-Related Enzyme TRIM55 and Autoimmune Heart Inflammation in Aicardi-Goutieres Syndrome
Official title: Importance of Muscle-Specific E3 Ligase TRIM55 in Autoimmune Myocarditis
Funded at Methodist Hospital Research Institute · NIH-11444135 · Data updated 2026-11-12
A new research project studies how a muscle-specific enzyme called TRIM55 drives autoimmune heart inflammation in a genetic syndrome.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 21, 2026 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $755,573 |
| NIH project number | 1R01HL182780-01A1 |
| Project ID | NIH-11444135 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with Aicardi-Goutières Syndrome who have or are at risk for autoimmune myocarditis, or who have related TRIM55-related immune features, may be eligible or represented in related future studies.
✕Less likely to help
People without autoimmune myocarditis or related TRIM55 signaling issues may not directly benefit from this specific research.
What this research studies
This project uses human cells from patients with Aicardi-Goutières Syndrome and a mouse model to understand how early immune signals in the heart may trigger autoimmune myocarditis. It found that reducing TRIM55 levels lowers harmful IFN-α signals and rescued heart inflammation in mice, suggesting TRIM55 is a key player. Researchers plan to further explore how TRIM55 links innate and autoimmune responses in the heart and test potential strategies to prevent damage. The work aims to reveal targets that could lead to new therapies for autoimmune heart disease in people with Aicardi‑Goutières Syndrome.
Why it matters
Potential benefit: If successful, this study could identify TRIM55 as a potential drug target to prevent or treat autoimmune myocarditis in patients.
How similar studies have gone: Previous work shows that manipulating similar immune pathways can alter heart inflammation in animal models, with this study adding a human disease context.
Where this research is happening
-
Methodist Hospital Research Institute
Houston, United States Active
Researchers
- Principal investigator: Xing, Junji — Methodist Hospital Research Institute
- Study coordinator: Xing, Junji
Related research
Other NIH-funded projects on the same topics.
-
Rapid bedside molecular imaging of heart inflammation with ultrasound
A fast, point-of-care ultrasound test using special contrast bubbles may help doctors quickly see active heart inflammation in people with chest pain or suspected ACS.
-
Targeted CXCR3 blockade to treat immunotherapy-related heart inflammation
A targeted drug approach aims to prevent or lessen heart inflammation caused by immune therapies in cancer patients, using CXCR3-blocking strategies.
-
Viral tricks that disrupt heart cell connections in myocarditis
This grant looks at how a common cold virus (adenovirus) may mess with the heart’s electrical signals and could lead to dangerous arrhythmias in people with myocarditis.
-
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor–Associated Heart Inflammation
A doctor-scientist team is studying why cancer patients treated with immune checkpoint drugs sometimes develop dangerous heart inflammation and what immune targets cause it.
-
Understanding how T cells and heart cells talk in a life-threatening heart inflammation from cancer immunotherapy
A doctor–scientist will study how immune T cells interact with heart cells in people treated for cancer who develop dangerous inflammation from immune checkpoint inhibitors.
-
CXCR6+ T-cells and ICI-related heart inflammation
A physician-scientist at UC San Francisco is studying how specific heart-damaging immune cells (CXCR6+ T-cells) contribute to dangerous heart inflammation caused by cancer immunotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.